In accordance, the work by Diem and colleagues revealed that coadministration of EPO and high dose methylprednisolone, a steroid medication in MS, had relatively higher potential to induce neuroprotection in RGCs and optic nerves, compared to respective monotherapies [115]. The gene discussed is EPO; the disease is myeloid sarcoma.